{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:17:03Z","timestamp":1790731023237,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Development of a malaria vaccine that blocks transmission of different parasite stages to humans and mosquitoes is considered critical for elimination efforts. A vaccine using Pfs25, a protein on the surface of zygotes and ookinetes, is under investigation as a transmission-blocking vaccine (TBV) that would interrupt parasite passage from mosquitoes to humans. The most extensively studied Pfs25 TBVs use <jats:italic>Pichia pastoris<\/jats:italic>-produced recombinant forms of Pfs25, chemically conjugated to a recombinant carrier protein, ExoProtein A (EPA). The recombinant form of Pfs25 first used in humans was identified as Pfs25H, which contained a total of 14 heterologous amino acid residues located at the amino- and carboxyl-termini including a His6 affinity tag. A second recombinant Pfs25, identified as Pfs25M, was produced to remove the heterologous amino acid residues and conjugated to EPA (Pfs25M-EPA). Here, monomeric Pfs25M was characterized biochemically and biophysically for identity, purity, and integrity including protein structure to assess its comparability with Pfs25H. Although the biological activities of Pfs25H and Pfs25M, whether generated by monomeric forms or conjugated nanoparticles, appeared similar, fine-mapping studies with two transmission-blocking monoclonal antibodies detected structural and immunological differences. In addition, evaluation of antisera generated against conjugated Pfs25H or Pfs25M nanoparticles in nonhuman primates identified polyclonal IgG that recognized these structural differences.<\/jats:p>","DOI":"10.1038\/s41541-023-00655-5","type":"journal-article","created":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T13:03:13Z","timestamp":1681563793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Structural and immunological differences in Plasmodium falciparum sexual stage transmission-blocking vaccines comprised of Pfs25-EPA nanoparticles"],"prefix":"10.1038","volume":"8","author":[{"given":"Nicholas J.","family":"MacDonald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vu","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Richard","family":"Shimp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos G.","family":"Gittis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Burkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoshan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Moler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duck-Yeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachy","family":"Orr-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4191-5675","authenticated-orcid":false,"given":"Jessica","family":"Herrod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn E.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Muratova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3826-1081","authenticated-orcid":false,"given":"Albert J.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Garboczi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4483-5005","authenticated-orcid":false,"given":"Patrick E.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3041-5402","authenticated-orcid":false,"given":"David L.","family":"Narum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,15]]},"reference":[{"key":"655_CR1","unstructured":"WHO. World Malaria Report 2021. (World Health Organization, 2021)."},{"key":"655_CR2","first-page":"61","volume":"97","author":"World Health Organization = Organisation mondiale de la, S. Weekly Epidemiological Record.","year":"2022","unstructured":"World Health Organization = Organisation mondiale de la, S. Weekly Epidemiological Record. Week. Epidemiol. Record = Relev\u00e9 \u00e9pid\u00e9miologique hebdomadaire 97, 61\u201380 (2022). 2022, vol. 97, 09 [full issue].","journal-title":"Week. Epidemiol. Record = Relev\u00e9 \u00e9pid\u00e9miologique hebdomadaire"},{"key":"655_CR3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jbiotec.2005.08.025","volume":"121","author":"CW Tsai","year":"2006","unstructured":"Tsai, C. W., Duggan, P. F., Shimp, R. L. Jr., Miller, L. H. & Narum, D. L. Overproduction of Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression, folding and O-linked glycosylation of a malaria vaccine candidate expressed in P. pastoris. J. Biotechnol. 121, 458\u2013470 (2006).","journal-title":"J. Biotechnol."},{"key":"655_CR4","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/S0264-410X(02)00701-6","volume":"21","author":"L Zou","year":"2003","unstructured":"Zou, L., Miles, A. P., Wang, J. & Stowers, A. W. Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials. Vaccine 21, 1650\u20131657 (2003).","journal-title":"Vaccine"},{"key":"655_CR5","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1007\/BF03401770","volume":"4","author":"T Tsuboi","year":"1998","unstructured":"Tsuboi, T. et al. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol. Med. 4, 772\u2013782 (1998).","journal-title":"Mol. Med."},{"key":"655_CR6","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1084\/jem.162.5.1460","volume":"162","author":"AN Vermeulen","year":"1985","unstructured":"Vermeulen, A. N. et al. Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito. J. Exp. Med. 162, 1460\u20131476 (1985).","journal-title":"J. Exp. Med."},{"key":"655_CR7","doi-asserted-by":"publisher","first-page":"e0163144","DOI":"10.1371\/journal.pone.0163144","volume":"11","author":"KR Talaat","year":"2016","unstructured":"Talaat, K. R. et al. Safety and Immunogenicity of Pfs25-EPA\/Alhydrogel(R), a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naive Adults. PLoS One 11, e0163144 (2016).","journal-title":"PLoS One"},{"key":"655_CR8","doi-asserted-by":"publisher","first-page":"e2636","DOI":"10.1371\/journal.pone.0002636","volume":"3","author":"Y Wu","year":"2008","unstructured":"Wu, Y. et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 3, e2636 (2008).","journal-title":"PLoS One"},{"key":"655_CR9","doi-asserted-by":"publisher","unstructured":"Healy, S. A. et al. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice. J. Clin. Investig. 131, https:\/\/doi.org\/10.1172\/JCI146221 (2021).","DOI":"10.1172\/JCI146221"},{"key":"655_CR10","doi-asserted-by":"publisher","first-page":"e0138761","DOI":"10.1371\/journal.pone.0138761","volume":"11","author":"DS Jones","year":"2016","unstructured":"Jones, D. S. et al. A method for producing protein nanoparticles with applications in vaccines. PLoS One 11, e0138761 (2016).","journal-title":"PLoS One"},{"key":"655_CR11","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1016\/j.vaccine.2013.04.034","volume":"31","author":"RL Shimp Jr.","year":"2013","unstructured":"Shimp, R. L. Jr. et al. Development of a Pfs25-EPA malaria transmission-blocking vaccine as a chemically conjugated nanoparticle. Vaccine 31, 2954\u20132962 (2013).","journal-title":"Vaccine"},{"key":"655_CR12","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S1473-3099(18)30344-X","volume":"18","author":"I Sagara","year":"2018","unstructured":"Sagara, I. et al. Safety and immunogenicity of Pfs25H-EPA\/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults. Lancet Infect. Dis. 18, 969\u2013982 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"655_CR13","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2010.04.036","volume":"28","author":"L Cheru","year":"2010","unstructured":"Cheru, L. et al. The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species. Vaccine 28, 4423\u20134429 (2010).","journal-title":"Vaccine"},{"key":"655_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01924-3","volume":"8","author":"SW Scally","year":"2017","unstructured":"Scally, S. W. et al. Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25. Nat. Commun. 8, 1568 (2017).","journal-title":"Nat. Commun."},{"key":"655_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11980-6","volume":"10","author":"B McLeod","year":"2019","unstructured":"McLeod, B. et al. Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25. Nat. Commun. 10, 4328 (2019).","journal-title":"Nat. Commun."},{"key":"655_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/srep40312","volume":"7","author":"AJ Radtke","year":"2017","unstructured":"Radtke, A. J. et al. Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate. Sci. Rep. 7, 40312 (2017).","journal-title":"Sci. Rep."},{"key":"655_CR17","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1084\/jem.174.5.1203","volume":"174","author":"PJ Barr","year":"1991","unstructured":"Barr, P. J. et al. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J. Exp. Med. 174, 1203\u20131208 (1991).","journal-title":"J. Exp. Med."},{"key":"655_CR18","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1186\/s13071-021-05078-6","volume":"14","author":"P Sookpongthai","year":"2021","unstructured":"Sookpongthai, P. et al. Global diversity of the gene encoding the Pfs25 protein-a Plasmodium falciparum transmission-blocking vaccine candidate. Parasit. Vectors 14, 571 (2021).","journal-title":"Parasit. Vectors"},{"key":"655_CR19","doi-asserted-by":"publisher","first-page":"e0266394","DOI":"10.1371\/journal.pone.0266394","volume":"17","author":"KO Ochwedo","year":"2022","unstructured":"Ochwedo, K. O. et al. Signatures of selection and drivers for novel mutation on transmission-blocking vaccine candidate Pfs25 gene in western Kenya. PLoS One 17, e0266394 (2022).","journal-title":"PLoS One"},{"key":"655_CR20","doi-asserted-by":"publisher","first-page":"19913","DOI":"10.1074\/jbc.M116.732305","volume":"291","author":"NJ MacDonald","year":"2016","unstructured":"MacDonald, N. J. et al. Structural and immunological characterization of recombinant 6-cysteine domains of the plasmodium falciparum sexual stage protein Pfs230. J. Biol. Chem. 291, 19913\u201319922 (2016).","journal-title":"J. Biol. Chem."},{"key":"655_CR21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s42003-020-01123-9","volume":"3","author":"K Singh","year":"2020","unstructured":"Singh, K. et al. Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48\/45 proteins. Commun. Biol. 3, 395 (2020).","journal-title":"Commun. Biol."},{"key":"655_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1128\/EC.00039-12","volume":"11","author":"O Uchime","year":"2012","unstructured":"Uchime, O. et al. Analysis of the conformation and function of the Plasmodium falciparum merozoite proteins MTRAP and PTRAMP. Eukaryotic Cell 11, 615\u2013625 (2012).","journal-title":"Eukaryotic Cell"},{"key":"655_CR23","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1128\/IAI.02676-14","volume":"83","author":"R Herrera","year":"2015","unstructured":"Herrera, R. et al. Reversible conformational change in the plasmodium falciparum circumsporozoite protein masks its adhesion domains. Infect. Immunity 83, 3771\u20133780 (2015).","journal-title":"Infect. Immunity"},{"key":"655_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jim.2005.07.021","volume":"306","author":"D Zhu","year":"2005","unstructured":"Zhu, D., Saul, A. J. & Miles, A. P. A quantitative slot blot assay for host cell protein impurities in recombinant proteins expressed in E. coli. J. Immunol. Methods 306, 40\u201350 (2005).","journal-title":"J. Immunol. Methods"},{"key":"655_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"655_CR26","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"655_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00655-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00655-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00655-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T13:06:11Z","timestamp":1681563971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00655-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,15]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["655"],"URL":"https:\/\/doi.org\/10.1038\/s41541-023-00655-5","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,15]]},"assertion":[{"value":"2 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}